Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 984 • 2013 ACR/ARHP Annual Meeting
Development and Usability Testing Of The Arthritis Health Journal: An Online Tool To Promote Self-Monitoring In People With Rheumatoid Arthritis
Erin Carruthers¹, Paul M Adam², Hilary Horlock³, Linda C. Li^4,5, Anne F. Townsend⁶, Charles H Goldsmith^7,8, Beverly Mitchell⁹ and Diane Lacaille^10,11, ¹Arthritis Research Centre of Canada, Richmond, BC, Canada, ²Rheumatology Liaison, Mary Pack Arthritis Centre, Vancouver, BC, Canada, ³Information Management / Information Technology Services, Provincial Health Services Authority, Vancouver, BC, Canada, ⁴Physical Therapy, University of British Columbia, Vancouver, BC, Canada, ⁵Physical Therapy, Arthritis Centre of Canada, Richmond, BC, Canada, ⁶Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁷Health Sciences, Simon Fraser University, Burnaby, BC, Canada, ⁸Biostatistics, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁹Business Solutions and Collaboration, Provincial Health Services Authority, Vancouver, BC, Canada, ¹⁰Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada, ¹¹Medicine, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Patient passports have been used in chronic diseases to promote the active involvement of patients in their care, and have led to better treatment…
Abstract Number: 2391 • 2013 ACR/ARHP Annual Meeting
Pathogenic Pro-Inflammatory Cytokine Production Induced By Synovial Fluid From RA Patients Is Related To Levels Of Endogenous TLR4 Ligands and Is Blocked By a Novel Therapeutic Anti-Human TLR4 Monoclonal Antibody, NI-0101
Limin Shang¹, Greg Elson¹, Jeremy Sokolove², Iain B. McInnes³, James Reilly⁴, Eric Hatterer¹, Marie Kosco-Vilbois⁵, Walter Ferlin⁵, Emmanuel Monnet⁵ and Cristina de Min⁶, ¹NovImmune S.A., Plan-Les-Ouates, Geneva, Switzerland, ²VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ³Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, United Kingdom, ⁴University of Glasgow, Glasgow, United Kingdom, ⁵NovImmune S.A., Geneva, Switzerland, ⁶Novimmmune S.A., Plan-Les-Ouates, Geneva, Switzerland
Background/Purpose: Deregulation of Toll-Like Receptor 4 (TLR4) signaling is thought to play a role in the pathogenesis of certain autoimmune diseases. In rheumatoid arthritis (RA),…
Abstract Number: 1945 • 2013 ACR/ARHP Annual Meeting
Comparison Of Selected Joint Evaluation With Comprehensive Assessment In Musculoskeletal Ultrasonography For Detection Of Synovitis In Rheumatoid Arthritis
Ryusuke Yoshimi¹, Atsushi Ihata¹, Yosuke Kunishita¹, Daiga Kishimoto¹, Reikou Kamiyama¹, Kaoru Minegishi¹, Maasa Hama¹, Yohei Kirino¹, Yukiko Asami¹, Atsuhisa Ueda¹, Mitsuhiro Takeno¹, Ichiro Aoki² and Yoshiaki Ishigatsubo¹, ¹Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Department of Molecular Pathology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
Background/Purpose: Musculoskeletal ultrasonography (US) is recognized as a useful tool for the diagnosis and monitoring of rheumatoid arthritis (RA), though a standard procedure has not…
Abstract Number: 938 • 2013 ACR/ARHP Annual Meeting
A Disintegrin and Metalloprotease-17 (ADAM-17) Is Expressed In Rheumatoid Arthritis and Mediates Monocyte Migration
Takeo Isozaki¹, Nao Oguro², Shinya Seki¹, Yoko Miura¹, Sho Ishii¹, Hiroyuki Tsukamoto¹, Takahiro Tokunaga¹, Masayu Umemura¹, Hidekazu Furuya¹, Ryo Yanai¹, Sakiko Isojima¹, Kuninobu Wakabayashi¹, Nobuyuki Yajima¹, Yusuke Miwa¹ and Tsuyoshi Kasama¹, ¹Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan, ²Div of Rhemuatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized byinflammation and joint destruction. Migration of monocytes/macrophages into the synovium is important in a variety…
Abstract Number: 2380 • 2013 ACR/ARHP Annual Meeting
Is Isoniazid Treatment For LTBI Safe For RA Patients With TNF Inhibitor Therapy?
Yoon-Kyoung Sung^1,2, Soo-Kyung Cho^1,2, Soyoung Won³, Jeeseon Shim³, Dam Kim⁴, Ji-Young Choi¹, Chan-Nam Son⁵, Chan-Bum Choi⁴, Tae-Hwan Kim⁶, Jae-Bum Jun⁶, Dae-Hyun Yoo⁶ and Sang-Cheol Bae^1,2, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Department of Rheumatology, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ³Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁴Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁵Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, South Korea, ⁶Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Isoniazid (INH) is increasingly used in RA patients with evidence of latent tuberculosis infection (LTBI) for whom TNF inhibitor therapy is planned. The potential for…
Abstract Number: 1948 • 2013 ACR/ARHP Annual Meeting
Power Doppler Ultrasound 7-Joint Score Vs. Simplified Disease Activity Index In Rheumatoid Arthritis Associated With Fibromyalgia
Rafael Chakr¹, Marina Behar², José A. Mendonça³, Daniela Cervantes², Nizele Calegaro², Nicole Andrade², Iuri Siqueira², Daniel Zanchet², Andrese Gasparin², Penélope Esther Palominos², Charles Kohem⁴, Odirlei Andre Monticielo⁵, Claiton Brenol⁶, Ricardo M. Xavier² and João Carlos T. Brenol⁷, ¹Rheumatology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ²Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ³Rheumatology, Pontifical Catholic University of Campinas / Institute of Clinical Research – IPECC, Campinas, Brazil, ⁴Brazilian Registry of Spondyloarthritis, São Paulo, Brazil, ⁵Department of Internal Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁶Universidade Federal do Rio Grande do Sul, Porto Alegre RS, Brazil, ⁷Rheumatology Division, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
Background/Purpose: Fibromyalgia (FM) falsely increases rheumatoid arthritis (RA) disease activity clinical composite scores, such as the simplified disease activity index (SDAI), recently incorporated into ACR/EULAR…
Abstract Number: 915 • 2013 ACR/ARHP Annual Meeting
IL-6R Inhibition Reduces Activation Of Different Peripheral Memory B Cell Subsets In RA
Zafar Mahmood¹, Khalid Muhammad¹, Marc Schmalzing², Petra Roll³, Kathrina Eckert¹, Thomas Dörner⁴ and Hans-Peter Tony⁵, ¹Rheumatology and Clinical Immunology, University of Würzburg, Würzburg, Germany, ²Rheumatology/Clinical Immunology, University Hospital Würzburg, Würzburg, Germany, ³Rheumatology and Clinical immunology, University of Würzburg, Würzburg, Germany, ⁴CC12, Dept. Medicine/Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany, ⁵Rheumatology/Clinical Immunology, University of Würzburg, Würzburg, Germany
Background/Purpose: Enhanced B cell activity has been proposed as part of the pathogenesis of rheumatoid arthritis also based on the clinical experiences obtained by B…
Abstract Number: 2383 • 2013 ACR/ARHP Annual Meeting
A Useful Mathematical Model Able To Predict The Early Response To Tocilizumab In Rheumatoid Arthritis
Chiara Stagnaro¹, Claudia Ferrari², Rosaria Talarico³, Camillo Giacomelli¹, Stefano Bombardieri¹ and Laura Bazzichi¹, ¹University of Pisa, Rheumatology Unit, Pisa, Italy, ²Rheumatology Unit, University of Pisa, Pisa, Italy, ³Rheumatology Unit, Pisa, Italy
Background/Purpose: In the last few year the introduction of biological agents has radically changed the clinical outcome of patients with Rheumatoid Arthritis (RA). However, no…
Abstract Number: 1888 • 2013 ACR/ARHP Annual Meeting
Transcriptional Regulation Of Peptidylarginine Deiminase Type IV: Implications For Rheumatoid Arthritis
Ali Abbas¹, Kevin Le¹, Virginia Pimmett¹, David A. Bell², Ewa Cairns² and Rodney P. DeKoter¹, ¹Microbiology and Immunology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ²Medicine, Division of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
Background/Purpose: High titers of anti-citrullinated protein/peptide antibodies (ACPA) have been detected in sera of rheumatoid arthritis (RA) patients, implicating citrullinating enzymes in the pathogenesis of…
Abstract Number: 877 • 2013 ACR/ARHP Annual Meeting
Results From The RATE-RA Study: A Multicenter, Single-Arm Study To Evaluate The Safety Of Administering Rituximab At a More Rapid Infusion Rate In Patients With Rheumatoid Arthritis
Charles H. Pritchard¹, Maria W. Greenwald², Joel M. Kremer³, Norman B. Gaylis⁴, William Rigby⁵, Steve Zlotnick⁶, Carol Chung⁷, Birgit Jaber⁸ and William Reiss⁹, ¹Rheumatology, Drexel University College of Medicine, Willow Grove, PA, ²Desert Medical Advances, Palm Desert, CA, ³Center for Rheumatology, Albany Medical College, Albany, NY, ⁴Arthritis & Rheumatic Disease Specialties, Aventura, FL, ⁵Department of Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁶Genentech, Inc., a Member of the Roche Group, South San Francisco, CA, ⁷Genentech Inc., South San Francisco, CA, ⁸F. Hoffmann-La Roche Ltd., Basel, Switzerland, ⁹Genentech, South San Francisco, CA
Background/Purpose: The FDA-approved dose of rituximab (RTX) in rheumatoid arthritis (RA) is 2 × 1000 mg IV infusions given 2 weeks apart (1 course), with…
Abstract Number: 2335 • 2013 ACR/ARHP Annual Meeting
Epstein-Barr Virus In Peripheral Blood Of Rheumatoid Arthritis Patients Predicts Response To Rituximab Therapy
Heikki Valleala¹, Markku Korpela², Markku J. Kauppi³ and Yrjo T. Konttinen⁴, ¹Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Helsinki, Finland, ²Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland, ³Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, ⁴Dept of Medicine, Helsinki Univ Central Hospital, Helsinki, Finland
Background/Purpose: Autoreactive B-cells infected by Epstein-Barr virus (EBV) are suspected to be involved in the aetiology of various human chronic autoimmune diseases. The aim of…
Abstract Number: 1833 • 2013 ACR/ARHP Annual Meeting
Combination Of TNF and IL-6 Induces Osteoclast-Like Cells With Bone-Resorption Activity Both In Vitro and In Vivo
Kazuhiro Yokota, Kojiro Sato and Toshihide Mimura, Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: Although TNF inhibitors suppress bone destruction in patients with rheumatoid arthritis (RA), TNFα stimulation alone does not directly induce osteoclasts, bone-resorbing cells. With the…
Abstract Number: 772 • 2013 ACR/ARHP Annual Meeting
Neovascularization and CD15s Influence Long Distance Migration Of Synovial Fibroblasts From Patients With Rheumatoid Arthritis
Birgit Zimmermann¹, Sina Köppert¹, Stephanie Lefèvre¹, Stefan Rehart², Ulf Müller-Ladner¹ and Elena Neumann³, ¹Internal Medicine and Rheumatology, Justus-Liebig-University of Gießen, Kerckhoff-Klinik, Bad Nauheim, Germany, ²Orthopedics and Trauma Surgery, Markus-Hospital, Frankfurt, Germany, ³Department of Internal Medicine and Rheumatology, Justus-Liebig-University of Gießen, Kerckhoff-Klinik, Bad Nauheim, Germany
Background/Purpose: Rheumatoid arthritis (RA) synovial fibroblasts (SF) are central cells of cartilage destruction and neoangiogenesis. RASF show an increased migratory potential in the synovium towards…
Abstract Number: 2342 • 2013 ACR/ARHP Annual Meeting
Long-Term Safety Of Rituximab: Pooled Analysis Of The Rheumatoid Arthritis Global Clinical Trial Program Over 11 Years
Ronald van Vollenhoven¹, Paul Emery^2,3, Clifton O. Bingham III⁴, Edward Keystone⁵, Roy Fleischmann⁶, Daniel Furst⁷, Eva W. Hessey⁸, Abdul Mehbob⁸ and Patricia B. Lehane⁹, ¹Karolinska Institute, Stockholm, Sweden, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁴Rheumatology, Johns Hopkins University, Baltimore, MD, ⁵University of Toronto, Toronto, ON, Canada, ⁶University of Texas Southwestern Medical Center, Dallas, TX, ⁷Medicine, University of California, Los Angeles, Los Angeles, CA, ⁸Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁹Roche Products Ltd, Welwyn Garden City, United Kingdom
Background/Purpose: This analysis evaluated the long-term safety of rituximab (RTX) in rheumatoid arthritis (RA) patients in a global clinical trial program. Methods: Pooled observed case…
Abstract Number: 1734 • 2013 ACR/ARHP Annual Meeting
A Phase Ib Clinical Trial With Dekavil (F8-IL10), An Immunoregulatory ‘Armed Antibody’ For The Treatment Of Rheumatoid Arthritis, Used In Combination With Methotrexate
M. Galeazzi¹, L Bazzichi², E Prisco³, G D Sebastiani⁴, D. Neri⁵, L Giovannoni⁶, F Bacchion⁷, M Bardelli¹, C Baldi¹, E Selvi¹, G Minisola⁸, R Caporali⁹ and S Bombardieri¹⁰, ¹Rheumatology Unit, University Hospital of Siena, Siena, Siena, Italy, ²Division of Rheumatology, University of Pisa, Pisa, Pisa, Italy, ³Rheumatology, Deptartment of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Pavia, Italy, ⁴Rheumatology Unit, San Camillo-Forlanini Hospital, Rome, Rome, Italy, ⁵Chemistry and Applied Sciences, Swiss Federal Institute of Technology, Zurich, Zurich, Switzerland, ⁶Clinical Research Unit, Philogen S.p.A., Siena, Sovicille - (SI), Italy, ⁷Clinical Research Unit, Philogen S.p.A, Siena, Sovicille - (SI), Italy, ⁸Rheumatology Unit, San Camillo-Forlanini Hospital, Rome, Rome, Italy, ⁹Department of Rheumatology, University of Pavia, IRCSS Policlinico San Matteo Foundation, Pavia, Pavia, Italy, ¹⁰Department of Clinical and Experimental Medicine, Department of Rheumatology, University of Pisa, Pisa, Pisa, Italy
Background/Purpose: A therapeutic strategy based on the selective delivery of an immuno-regulatory cytokine to the sites of inflammatory disease has been developed. DEKAVIL is an…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.